Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01463631 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3007113 in Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01463631: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT01463631 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01463631, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study evaluates the safety and tolerability of different doses of an experimental treatment in participants with advanced cancer.
Primary Outcome
Data presented are the number of participants who experienced at least one treatment emergent adverse event (TEAE). A TEAE is defined as an event that first occurred or worsened after randomization. A summary of serious AEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.
Interventions
- DRUG LY3007113
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT01463631 record still lists
NCT01463631 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which LY3007113 is the first listed.
NCT01463631 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01463631 about?
NCT01463631 is a clinical study titled "A Study of LY3007113 in Participants With Advanced Cancer". This study evaluates the safety and tolerability of different doses of an experimental treatment in participants with advanced cancer.
What is the current status of trial NCT01463631?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01463631?
The interventions under investigation include: LY3007113 (DRUG).
Who is sponsoring clinical trial NCT01463631?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01463631's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia